NeoGenomics RNA-based NGS Fusion Detection
With over 500 recurrent fusion genes known in hematologic and solid tumor cancers, fusion testing is creating new paths in cancer diagnosis, treatment selection, and clinical trial options. Although gene fusions are individually uncommon, they have a high combined prevalence and are identifiable by NGS in up to 17% of solid tumors. RNA-based sequencing optimizes reach and sensitivity over DNA-based assays to accommodate fusion diversity. NeoGenomics offers a broad suite of 17 RNA-based solid tumor fusion panels that identify current and anticipated future targetable biomarkers. To learn more about adopting fusion testing into comprehensive genomic profiling, please watch our Industry Expert Theater session “New Tests, New Challenges: Fitting Fusions into the CGP Puzzle,” presented by Dr. Sally Agersborg, Medical Director, NeoGenomics. The session will be available on demand from May 14 to July 6....
More Info Less Info